Abstract
Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer, tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous chromosomal abnormality, and the side effects of current chemotherapies are some of challenges that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC) opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel treatment based on iPSC technology.
Keywords: Leukemia, iPSC, treatment, reprogrammed NK cells, miRNAs, gene therapy, iHSC, malignancy modeling.
Current Stem Cell Research & Therapy
Title:A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future
Volume: 13 Issue: 8
Author(s): Amirhosein Maali, Amir Atashi, Sasan Ghaffari, Reza Kouchaki, Fereshteh Abdolmaleki and Mehdi Azad*
Affiliation:
- Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin,Iran
Keywords: Leukemia, iPSC, treatment, reprogrammed NK cells, miRNAs, gene therapy, iHSC, malignancy modeling.
Abstract: Leukemia is an uncontrollable growth of hematopoietic cells due to a mutation in DNA followed by cellular dysregulation and one or more chromosomal disorder that generally leads to a clonal abnormality. Theoretical and technical inability in early screening and distinguishing cancer, tumor tolerance to common treatment methods, repeated relapses of cancer after remission phase, heterogeneous chromosomal abnormality, and the side effects of current chemotherapies are some of challenges that we face with leukemia and other malignancies. Induced pluripotent stem cells (iPSC) opened a promising window to a wide range of diseases, including leukemia. Overcoming the barriers in leukemia is possible with iPSC technology. Induced hematopoietic stem cell transplantation (and gene therapy), induced cytotoxic T-lymphocytes and reprogrammed NK cells that strengthen the immune system, miRNAs, modeling approaches, and supportive cares are some aspects of the novel treatment based on iPSC technology.
Export Options
About this article
Cite this article as:
Maali Amirhosein , Atashi Amir , Ghaffari Sasan , Kouchaki Reza , Abdolmaleki Fereshteh and Azad Mehdi *, A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future, Current Stem Cell Research & Therapy 2018; 13 (8) . https://dx.doi.org/10.2174/1574888X13666180731155038
DOI https://dx.doi.org/10.2174/1574888X13666180731155038 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atopic Dermatitis in the Elderly
Inflammation & Allergy - Drug Targets (Discontinued) Stem Cell Genetic Therapy for Fanconi Anemia – A New Hope
Current Gene Therapy Novel Approaches in the Synthesis of Batracylin and Its Analogs: Rebirth of an Old Player?
Current Medicinal Chemistry Synthesis and Biological Potential Assessment of 2-Substituted Quinazolin-4(3<i>H</i>)-ones as Inhibitors of Phosphodiesterase-I and Carbonic Anhydrase-II
Medicinal Chemistry Cellular and Molecular Mechanisms of Apoptosis in Age-Related Muscle Atrophy
Current Aging Science Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
Current Cancer Drug Targets Docking Studies of Glutamine Valproic Acid Derivative (S)-5- amino-2-(heptan-4-ylamino)-5-oxopentanoic Acid (Gln-VPA) on HDAC8 with Biological Evaluation in HeLa Cells
Anti-Cancer Agents in Medicinal Chemistry miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications
Current Pharmaceutical Design Bioinformatics Approach to BDNF and BDNF-Related Disorders
Current Neuropharmacology Immune Related Genes Underpin the Evolution of Adaptive Immunity in Jawless Vertebrates
Current Genomics Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Indication of Bevacizumab for Cerebral Radiation Necrosis
Recent Patents on Anti-Cancer Drug Discovery Laccases in Pharmaceutical Chemistry: A Comprehensive Appraisal
Mini-Reviews in Organic Chemistry Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology Efficient Gene Selection for Cancer Prognostic Biomarkers Using Swarm Optimization and Survival Analysis
Current Bioinformatics Synthesis and Biological Activity of Some Nucleoside Analogs of 3-Cyanopyridin-2- one
Current Organic Synthesis